Clostridium (e.g., Clostridium Tetani, Clostridium Difficile, Clostridium Perfringens, Clostridium Botulinum, Clostridium Chauvoei, Etc.) Patents (Class 424/247.1)
-
Patent number: 7691394Abstract: The present invention provides improved formulations of botulinum toxin that increase delivery of the botulinum toxin to neural and associated tissues and exhibit a higher specific neurotoxicity and higher potency (in LD50 Units) than available formulations of botulinum toxins. These improved formulations enable physicians to treat a wide variety of pathological conditions with a lower toxin load that reduces the risk of inducing an immune response against the toxin and its associated proteins that may ultimately lead to the development of toxin resistance. These benefits are particularly important in the treatment of conditions that require high-dose or chronic administration of botulinum toxin. Additionally, the decreased in LD50 Unit doses of inventive formulations allows for controlled administration limits diffusion. The present invention also provides methods of treating neuromuscular diseases and pain, using low-dose botulinum toxin.Type: GrantFiled: April 22, 2005Date of Patent: April 6, 2010Assignee: Botulinum Toxin Research Associates, Inc.Inventor: Gary E. Borodic
-
Publication number: 20100062025Abstract: The present invention relates to the use of a vaccine comprising Clostridium perfringens type C bacterium for protecting swine against Clostridium perfringens type A infection.Type: ApplicationFiled: November 19, 2007Publication date: March 11, 2010Applicant: Intervet International B.V.Inventors: Maarten Hendrik Witvliet, Jozef Franciscus Maria Smeets, Keith Redhead
-
Patent number: 7674470Abstract: Antigenic compositions are provided comprising a single chain polypeptide comprising first and second domains, wherein said first domain is a clostridial neurotoxin light chain or a fragment or a variant thereof and is capable of cleaving one or more vesicle or plasma membrane associated proteins essential to exocytosis; and said second domain is a clostridial neurotoxin heavy chain HN portion or a fragment or a variant thereof, wherein said second domain is capable of (i) translocating the polypeptide into a cell or (ii) increasing the solubility of the polypeptide compared to the solubility of the first domain on its own or (iii) both translocating the polypeptide into a cell and increasing the solubility of the polypeptide compared to the solubility of the first domain on its own; and wherein the second domain lacks a functional C-terminal part of a clostridial neurotoxin heavy chain designated HC thereby rendering the polypeptide incapable of binding to cell surface receptors that are the natural cell surType: GrantFiled: March 11, 2005Date of Patent: March 9, 2010Assignees: Health Protection Agency, Syntaxin LimitedInventors: Charles Clifford Shone, Conrad Padraig Quinn, Keith Alan Foster, John Chaddock, Philip Marks, J. Mark Sutton, Patrick Stancombe, Jonathan Wayne
-
Patent number: 7670608Abstract: Botulinum toxin has been shown to be useful for the treatment of pain when administered for cervical dystonia. Given efficacy for pain relief in regional dystonia, further expanded applications have included myofascial pain, muscle tension headaches, and other forms of headache syndromes. The application in headache practice has expanded to migraine as well as certain secondary headache syndromes. Although multiple case reports involving the use of botulinum toxin have shown promise in its utility for the treatment of primary pain syndromes, to date, controlled trials have failed to consistently and more definitively prove utility. Described herein is a method for selection of patients with headache syndromes more likely to respond to botulinum administration.Type: GrantFiled: March 8, 2004Date of Patent: March 2, 2010Assignee: Botulinum Toxin Research Associates, Inc.Inventor: Gary Borodic
-
Publication number: 20100028448Abstract: Disclosed herein are immunogenic compositions comprising a multilayer film comprising two or more layers of polyelectrolytes, wherein adjacent layers comprise oppositely charged polyelectrolytes. A first layer polyelectrolyte comprises an antigenic polypeptide comprising one or more surface adsorption regions covalently linked to one or more antigenic determinant regions, wherein the antigenic polypeptide and the one or more surface adsorption regions have the same polarity. The immunogenic compositions may be employed in methods of eliciting an immune response in a vertebrate organism.Type: ApplicationFiled: October 5, 2009Publication date: February 4, 2010Applicant: ARTIFICIAL CELL TECHNOLOGIES, INC.Inventor: Donald T. Haynie
-
Patent number: 7655243Abstract: Methods and systems for delivering toxin and toxin fragments to a patient's nasal cavity provide for both release of the toxin and delivery of energy which selectively porates target cells to enhance uptake of the toxin. The use of energy-mediated delivery is particularly advantageous with light chain fragment toxins which lack cell binding capacity.Type: GrantFiled: May 18, 2007Date of Patent: February 2, 2010Assignee: The Foundry, LLCInventors: Mark E. Deem, Hanson Gifford
-
Publication number: 20100021546Abstract: Single-dose controlled-release immunogenic formulations, such as vaccines, based on bioerodible polyanhydride copolymer or homopolymer microparticles for the control of immune response mechanisms are provided. The copolymer or homopolymer microparticles degrade by surface-erosion from in vivo hydrolysis of anhydride linkages at the surface of the microparticle, which results in controlled release of immunogen(s) to a patient.Type: ApplicationFiled: September 4, 2009Publication date: January 28, 2010Applicant: Iowa State University Research Foundation, Inc.Inventors: Matthew J. Kipper, Balaji Narasimhan, Jennifer H. Wilson, Michael J. Wannemuehler
-
Patent number: 7635484Abstract: The present invention provides BoNT/A peptides as well as methods of predicting or determining immunoresistance to botulinum toxin therapy in an individual using BoNT/A peptides.Type: GrantFiled: March 29, 2007Date of Patent: December 22, 2009Assignees: Allergan, Inc., Baylor College of MedicineInventor: M. Zouhair Atassi
-
Patent number: 7628992Abstract: A chemical conjugate for treating a nerve cell related disorder is provided. This conjugate includes an active or inactive Clostridial toxin having specificity for a target nerve cell. The toxin is conjugated to a drug or other bioactive molecule without affecting the toxin's ability to enter the target nerve cell.Type: GrantFiled: September 28, 2000Date of Patent: December 8, 2009Assignee: Invent DCU LimitedInventors: James Oliver Dolly, Larry Allen Wheeler, Kei Roger Aoki, Michael Elwood Garst
-
Publication number: 20090297559Abstract: The present invention provides materials and methods to facilitate the pulmonary delivery of therapeutic agents. In some embodiments, agonists of tight junctions (e.g., zonulin agonists) are used in compositions to facilitate the uptake of therapeutic agents from the pulmonary mucosa.Type: ApplicationFiled: July 6, 2009Publication date: December 3, 2009Inventors: Alessio FASANO, Blake Paterson
-
Patent number: 7625559Abstract: Antibodies that specifically bind to toxins of C. difficile, antigen binding portions thereof, and methods of making and using the antibodies and antigen binding portions thereof are provided herein.Type: GrantFiled: February 4, 2005Date of Patent: December 1, 2009Assignees: University of Massachusetts, Medarex, Inc.Inventors: Donna Ambrosino, Gregory J. Babcock, Teresa Broering, Robert Graziano, Hector Javier Hernandez, Israel Lowy, Robert Mandell, Deborah Molrine, William D. Thomas, Jr., Hui-Fen Zhang
-
Patent number: 7608275Abstract: Methods and apparatus are provided for applying an fragment of a neurotoxin such as the active light chain (LC) of the botulinum toxin (BoNT), such as one of the serotype A, B, C, D, E, F or G botulinum toxins, via permeabilization of targeted cell membranes to enable translocation of the botulinum neurotoxin light chain (BoNT-LC) molecule across the targeted cell membrane to the cell cytosol where a therapeutic response is produced in a mammalian system. The methods and apparatus include use of catheter based delivery systems, non-invasive delivery systems, and transdermal delivery systems.Type: GrantFiled: July 21, 2006Date of Patent: October 27, 2009Assignee: The Foundry, LLCInventors: Mark E. Deem, Hanson Gifford
-
Publication number: 20090214466Abstract: The invention relates generally to the field of treatment of headache, post-laminectomy syndrome, and other disorders associated with localized pain. The compositions and methods described herein are useful for alleviating both the disorders and the pain associated therewith.Type: ApplicationFiled: May 9, 2006Publication date: August 27, 2009Inventor: Bruce H. Levin
-
Publication number: 20090214537Abstract: A newly identified serum resistance factor of gram positive bacteria can be used to treat or prevent bacterial infection.Type: ApplicationFiled: May 12, 2006Publication date: August 27, 2009Applicant: NOVARTIS VACCINES AND DIAGNOSTICS, INC.Inventors: Marco Soriani, Isabella Santi
-
Patent number: 7579010Abstract: A botulinum toxin pharmaceutical formulation free of animal derived proteins, comprising a botulinum toxin and a recombinant albumin, suitable for therapeutic administration to a human patient, and methods for treating patients with various diseases and afflictions with the formulation.Type: GrantFiled: October 29, 2004Date of Patent: August 25, 2009Assignee: Allergan, Inc.Inventor: Terrence J. Hunt
-
Publication number: 20090181054Abstract: The present invention describes derivatized polysaccharide-protein conjugates, a composition comprising one or more of such derivatized polysaccharide-protein conjugates and methods of immunizing human patients with the same. The derivatized polysaccharide-protein conjugates are purified capsular polysaccharides from Neisseria meningitidis serogroups A, C, W-135, and Y, derivatized chemically activated and selectively attached to a carrier protein by means of a covalent chemical bond, forming polysaccharide-protein conjugates capable of eliciting long-lasting immunity to a variety of N. meningitidis strains.Type: ApplicationFiled: March 2, 2009Publication date: July 16, 2009Inventor: Robert P. Ryall
-
Publication number: 20090169636Abstract: Immunogenic compositions are described herein which comprise microparticles that further comprise a biodegradable polymer. The microparticle compositions also comprise a cationic polysaccharide and an immunological species selected from an antigen, an immunological adjuvant and a combination thereof. Also described are methods of making such compositions and methods of administering such compositions. Methods of modulating the release rate of immunological species from microparticles are also described. These methods comprise varying the ratio of the cationic polysaccharide relative to the biodegradable polymer within the microparticles.Type: ApplicationFiled: February 24, 2007Publication date: July 2, 2009Inventors: Derek O' Hagan, Manmohan Singh, Janet Wendorf, Jina Kazzaz, Padma Malyala
-
Publication number: 20090136623Abstract: The present invention relates to growth-inhibitory composition against pathogenic bacteria of meat based food stuff comprising IgY, a specific immunoglobulin derived from yolk of egg. The 12 representative bacteria and other microbes deteriorating quality of process meat products that the IgY of the present invention targets include Aeromonas hydrophila, Bacilluis cereus, Campylobacter jejuni, Clostridium perfringens, 0157: H7 (Escherichia coli 0157:H7), Lactobacillus, Listeria monocytogens, Sacromyces cerevisae, Salmonella enteritidis, Salmonella typhimurium, Staphylococcus aureus, and Staphylococcus epidermidis. As the form of antigen, the 12 bacteria are injected to chickens separately to obtain IgY of the present invention against the 12 pathogens.Type: ApplicationFiled: March 12, 2007Publication date: May 28, 2009Inventor: Min-Seok SONG
-
Patent number: 7531179Abstract: The present invention provides BoNT/A peptides as well as methods of predicting or determining immunoresistance to botulinum toxin therapy in an individual using BoNT/A peptides.Type: GrantFiled: March 29, 2007Date of Patent: May 12, 2009Assignee: Allergan, Inc.Inventor: M. Zouhair Atassi
-
Publication number: 20090110699Abstract: Vitreous compositions of an antigen and adjuvant, and methods for making the compositions are disclosed. Also disclosed are pharmaceutically acceptable formulations of the vitreous compositions, reconstituted liquid formulations of the vitreous compositions, vaccine compositions, and kits containing the vitreous compositions. Also disclosed are devices for administering the vitreous compositions to mammals and methods for eliciting an immune response in mammals by administering the compositions.Type: ApplicationFiled: July 25, 2008Publication date: April 30, 2009Inventors: Sandrine Cigarini, Kevin Harper, Manvi Hasija
-
Publication number: 20090092639Abstract: Methods and compositions for increasing antibody titer in egg yolks and for using the antibodies are disclosed.Type: ApplicationFiled: December 17, 2008Publication date: April 9, 2009Inventors: Mark E. Cook, David L. Trott, Mingder Yang
-
Patent number: 7514088Abstract: The present invention is directed to multivalent Clostridial neurotoxin derivatives having more than one binding domain directed to a cell surface feature of a target cell. Such modified neurotoxins are useful as therapeutic compositions to prevent exocytosis and secretion by the target cell. Conditions in which such compositions man be useful include, without limitation, disorders of the sensory or motor nervous system, acute or chronic pain, cancer, pancreatitis, hyperhydrosis, glandular disorders, viral infections, cystic fibrosis and the like. The invention is also directed to methods of using and administering such a composition, and methods of treating a given condition using such a composition.Type: GrantFiled: March 15, 2006Date of Patent: April 7, 2009Assignee: Allergan, Inc.Inventors: Lance E. Steward, Fernandez-Salas Ester, Joseph Francis, Shengwin Li, Marcella A. Gilmore, Kei Roger Aoki
-
Patent number: 7507419Abstract: Hyperactive glandular conditions are treated using topically formulated botulinum toxin compositions. In the preferred embodiment of the invention, topical botulinum preparations are applied directly to the skin by a patient as needed to suppress his or her hyperhidrosis, bromhidrosis, chromhidrosis, nevus sudoriferous, acne, seborrhiec dermatitis or other glandular condition. In other embodiments, topical botulinum toxins are applied with the aid of mechanical, electrical, and/or chemical transdermal delivery enhancers.Type: GrantFiled: July 10, 2006Date of Patent: March 24, 2009Inventor: William P. Coleman, III
-
Patent number: 7494654Abstract: The present invention provides for methods of treating cardiovascular diseases in a mammal. The methods include a step of administering an effective amount of a botulinum toxin directly to a blood vessel of a mammal thereby treating a cardiovascular disease.Type: GrantFiled: June 16, 2004Date of Patent: February 24, 2009Assignee: Allergan, Inc.Inventors: Gregory F. Brooks, Stephen Donovan
-
Patent number: 7494661Abstract: Methods of using tetanus toxin to modulate or control neural functions or nonneural cellular activities at selected sites in animals, particularly in mammals, and more particularly in humans, are provided. Pharmaceutical formulations to modulate neural functions or non-neural cellular activities of an animal at selected sites in animals, particularly in mammals, and more particularly in humans are also provided. Uses of tetanus toxin in preparation of medicaments for methods of treating clinical disorders or symptoms of animals, particularly mammals and more particularly humans are also provided.Type: GrantFiled: June 28, 2001Date of Patent: February 24, 2009Inventor: Ira Sanders
-
Patent number: 7491403Abstract: Botulinum toxin, a well know systemic poison, produces favorable therapeutic effect by virtue of regionally attaching to nerves within the myoneural junction and possibly other tissues in a target region of a particular tissue. The present invention provides compositions of botulinum toxin and a sequestration agent that increase sequestration and delivery of the botulinum toxin to neural and associated tissues, as compared with available formulations of botulinum toxins, and thereby produce a beneficial clinical effect. The sequestration agents of the present invention include proteins, lipids and carbohydrates. A preferred composition of the present invention comprises a botulinum toxin and an albumin. The present invention also provides methods of treating neuromuscular diseases and pain using the disclosed compositions and methods of making the disclosed compositions.Type: GrantFiled: December 22, 2003Date of Patent: February 17, 2009Assignee: Botulinum Toxin Research AssociatesInventor: Gary Borodic
-
Publication number: 20090010964Abstract: The invention provides for a method of enhancing immunological responses to an antigen in a vaccine formulation, and for a vaccine formulation that provides for an enhanced immunological response to an antigen. In the method and formulation the antigen is administered with an adjuvant which adjuvant comprises a solution of nitrous oxide gas in a pharmaceutically acceptable carrier solvent for the gas and which adjuvant includes at least one fatty acid or ester or other suitable derivative thereof selected from the group consisting of oleic acid, linoleic acid, alpha-linolenic acid, gamma-linolenic acid, arachidonic acid, eicosapentaenoic acid [C20: 5?3], decosahexaenoic acid [C22: 6?3], ricinoleic acid and derivatives thereof selected from the group consisting of the C1 to C6 alkyl esters thereof, the glycerol-polyethylene glycol esters thereof and the reaction product of hydrogenated natural oils composed largely of ricinoleic acid based oils, such as castor oil with ethylene oxide.Type: ApplicationFiled: August 3, 2006Publication date: January 8, 2009Inventors: Anne Grobler, Abraham Frederik Kotze
-
Patent number: 7473429Abstract: The present invention generally relates to methods for treating the sequela of laminitis in hoofed animals. Benefits are obtained by administering to the animals to be treated injections of Botulinum Toxin in the limb to be treated. In one embodiment, about 100 Units to 600 Units of Type A Botulinum Toxin is injected in multiple injections into the flexor digitorum profundus muscle of an animal's affected limb.Type: GrantFiled: July 27, 2007Date of Patent: January 6, 2009Inventors: J. Ben Renfroe, Daniel W. Carter
-
Patent number: 7465458Abstract: The present invention provides methods of treating an eye disorder. The methods comprise a step of locally administering a Clostridial toxin to the eye of a patient to treat the disorder. The eye disorder may be associated with an inflammation of the eye, including for example, bacterial conjunctivitis, fungal conjunctivitis, viral conjunctivitis, uveitis, keratic precipitates, macular edema, and inflammation response after intra-ocular lens implantation. The Clostridial toxin may be produced by a Clostridial beratti, a Clostridia butyricum, a Clostridial tetani bacterium and/or a Clostridial botulinum.Type: GrantFiled: April 19, 2007Date of Patent: December 16, 2008Assignee: Allergan, Inc.Inventor: Eric R. First
-
Patent number: 7455845Abstract: The present invention related to methods for treating neurological-urological conditions, including urinary retention. This is accomplished by administration of a botulinum toxin into the lower urinary tract of a patient with urinary retention, including the bladder or urinary sphincter and the bladder wall.Type: GrantFiled: February 13, 2004Date of Patent: November 25, 2008Assignee: The Regents of the University of ColoradoInventors: David Allen, legal representative, Richard A. Schmidt
-
Patent number: 7449192Abstract: The present invention related to methods for treating neurological-urological conditions, including neurogenic bladder dysfunction. This is accomplished by administration of a botulinum toxin into the lower urinary tract of a patient with a neurogenic bladder dysfunction, including the bladder or urinary sphincter and the bladder wall.Type: GrantFiled: February 13, 2004Date of Patent: November 11, 2008Assignee: The Regents of the University of ColoradoInventor: Richard A. Schmidt
-
Patent number: 7429386Abstract: Methods for treating stretch marks by local administration of a Clostridial toxin, such as a botulinum toxin, to a patient with a stretch mark.Type: GrantFiled: September 3, 2004Date of Patent: September 30, 2008Assignee: Allergan, Inc.Inventor: Eric R. First
-
Patent number: 7422753Abstract: Methods for treating trichotillomania by local administration of a Clostridial toxin. The local administration can be by intramuscular, transdermal, intradermal or subdermal administration of a low dose of botulinum toxin.Type: GrantFiled: April 25, 2003Date of Patent: September 9, 2008Assignee: Allergan, Inc.Inventor: Alan H. Ackerman
-
Publication number: 20080213316Abstract: Methods for enhancing destruction and killing of bacterial spores via phagocytosis, where phagocytosis of bacterial spores is enhanced by using a glycoconjugate. In one embodiment, the method includes the steps of modifying a surface of a bacterial spore to increase adherence to a phagocyte; and ingesting the adherence-increased spore with the phagocyte, thereby destructing and killing the spore by blocking spore-induced phagocyte cell death, while increasing phagocyte activation level and production of antimicrobial and cytocidal agents such as NO and inflammatory cytokines. The adherence of spore to a phagocyte is increased after the surface thereof is coated with a glycoconjugate to form a glycoconjugate-coated spores. The glycoconjugate-coated spores also increase ingestion of the spores by phagocytes and facilitate phagosome-lysosome fusion, which in turn results in destruction and killing of bacterial spores via phagocytosis.Type: ApplicationFiled: February 22, 2007Publication date: September 4, 2008Inventor: Olga Tarasenko
-
Patent number: 7419675Abstract: Methods for treating peritoneal adhesions by local administration of a Clostridial toxin, such as a botulinum toxin, to a patient with a peritoneal adhesion.Type: GrantFiled: May 26, 2005Date of Patent: September 2, 2008Assignee: Allergan, Inc.Inventor: Eric R. First
-
Patent number: 7396535Abstract: Methods for treating a head banging disorder by local administration of a Clostridial toxin. The local administration can be by intramuscular, transdermal, intradermal or subdermal administration of a low dose of botulinum toxin.Type: GrantFiled: April 25, 2003Date of Patent: July 8, 2008Inventor: Alan H. Ackerman
-
Patent number: 7393538Abstract: Methods for treating a dermatillomania by local administration of a Clostridial toxin. The local administration can be by intramuscular, transdermal, intradermal or subdermal administration of a low dose of botulinum toxin.Type: GrantFiled: April 25, 2003Date of Patent: July 1, 2008Inventor: Alan H. Ackerman
-
Patent number: 7393537Abstract: Methods for treating obsessions and compulsions by local administration of a Clostridial toxin. The obsessions or compulsions can be eye poking, body rocking, finger biting, counting, checking and related disorders treated by low dose, intramuscular administration of a botulinum toxin.Type: GrantFiled: April 25, 2003Date of Patent: July 1, 2008Assignee: Allergan, Inc.Inventor: Alan H. Ackerman
-
Patent number: 7390496Abstract: Methods for treating a hand washing disorder by local administration of a Clostridial toxin. The local administration can be by intramuscular, transdermal, intradermal or subdermal administration of a low dose of botulinum toxin.Type: GrantFiled: April 25, 2003Date of Patent: June 24, 2008Assignee: Allergan, Inc.Inventor: Alan H. Ackerman
-
Patent number: 7384918Abstract: The invention provides for the use of a botulinum toxin to treat contracture, such as muscle contracture, in patients by transdermal administration of the botulinum toxin.Type: GrantFiled: August 22, 2005Date of Patent: June 10, 2008Assignee: Allergan, Inc.Inventor: Herbert Kerr Graham
-
Patent number: 7378389Abstract: The invention provides for the use of a presynaptic neurotoxin (for example a bacterial neurotoxin such as botulinum toxin A) for the manufacture of a medicament for the treatment of cerebral palsy in juvenile patients. The juvenile patients are preferably juveniles of up to 6 years in age.Type: GrantFiled: May 22, 2007Date of Patent: May 27, 2008Assignee: Allergan, Inc.Inventor: Herbert Kerr Graham
-
Patent number: 7323179Abstract: The invention features methods and compositions for treatment or prevention of infection by, or disease caused by infection with, certain species of bacteria, including in particular bacteria in which a RAP-type and/or TRAP-type molecule plays a role in pathogenesis. This includes Staphylococcus species.Type: GrantFiled: February 3, 2003Date of Patent: January 29, 2008Inventor: Naomi Balaban
-
Patent number: 7309493Abstract: Inactivated scours vaccines for immunization and protection of bovine animals from disease caused by infection with bovine rotavirus and bovine coronavirus, which comprise and effective amount of at least one inactivated viral strain are described. Polyvalent inactivated vaccines further comprising an effective amount of an antigenic component which is protective against one or more additional pathogenic organisms or viruses are also disclosed. Said vaccines are prepared from one or more strains of rota- and coronavirus, C. perfringens Type C bacteria and E. coli bacteria, and combinations thereof. Preferably, a polyvalent inactivated vaccine is provided for parenteral administration. Passive immunity is achieved in neonatal calves via immunization of pregnant cows prior to birth.Type: GrantFiled: August 1, 2005Date of Patent: December 18, 2007Assignee: Novartis AGInventors: Kelly Knape, Stephanie Dykstra, Mary Tinant
-
Patent number: 7279169Abstract: Mucosal DTPa vaccines, especially intranasal vaccines, comprising (a) a diphtheria antigen, a tetanus antigen and an acellular pertussis antigen, and (b) a detoxified mutant of cholera toxin (CT) or E. coli heat labile toxin (LT). Component (b) acts as a mucosal adjuvant. The acellular pertussis antigen preferably comprises pertussis holotoxin (PT) and filamentous haemagglutinin (FHA) and, optionally, pertactin. The mucosally-delivered combined DTPa formulation is capable of generating a level of protection against B. pertussis infection equivalent to that observed by alum-adjuvanted parenteral administration.Type: GrantFiled: September 28, 2000Date of Patent: October 9, 2007Assignee: Novartis Vaccines and Diagnostics SRLInventors: Rino Rappuoli, Mariagrazia Pizza
-
Patent number: 7276473Abstract: Methods and compositions for the treatment of acute pancreatitis in a mammal. Particular compositions comprise a binding element, a translocation element, and a therapeutic element able to prevent accumulation of digestive enzymes within the pancreas.Type: GrantFiled: April 23, 2004Date of Patent: October 2, 2007Assignee: Allergan, Inc.Inventors: George Sachs, Kei Roger Aoki
-
Patent number: 7232571Abstract: The invention describes therapeutic compositions including a lactic acid-producing bacteria, such as isolated Bacillus coagulans, in combination with a bifidogenic oligosaccharides or other cholesterol-reducing agents for use in reducing LDL cholesterol and serum triglycerides. Also described are therapeutic methods using the compositions and systems containing the therapeutic compositions.Type: GrantFiled: November 1, 2004Date of Patent: June 19, 2007Assignee: Ganeden Biotech, Inc.Inventors: Scan Farmer, Andrew R. Lefkowitz
-
Patent number: 7229626Abstract: Methods for treating psychiatric disorders include intracranial administration of a therapeutically effective amount of a neurotoxin, such as a botulinum toxin type A, to a human patient.Type: GrantFiled: March 22, 2004Date of Patent: June 12, 2007Assignee: Allergan, Inc.Inventor: Stephen Donovan
-
Patent number: 7229605Abstract: Methods for determining the effect of a Clostridial neurotoxin on muscle are disclosed. In particular, methods for determining a potency and/or diffusion of a neurotoxin based on a nuclear index and/or an amount of muscle atrophy are disclosed. The methods may be used to distinguish two different Clostridial neurotoxins. In certain embodiments, the neurotoxins are obtained from Clostridium botulinum.Type: GrantFiled: August 13, 2004Date of Patent: June 12, 2007Assignee: Allergan, Inc.Inventors: James M. Holland, Edward Chow
-
Patent number: 7226605Abstract: Botulinum toxin may be used to inhibit the cascade of events leading to acne. Results in preliminary studies have been dramatic. Without wishing to be bound by this theory, it is believed that botulinum toxin achieves this result through parasympathetic effects, inhibiting sweat gland activity, stimulating keratinocyte locomotion, anti-inflammatory effects, and possibly anti-androgenic effects. Botulinum toxin can play an important role in decreasing and even preventing the formation of acne.Type: GrantFiled: July 25, 2002Date of Patent: June 5, 2007Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical CollegeInventors: Dana L. Suskind, Ann H. Tilton, Mary L. Caire
-
Patent number: 7223399Abstract: The present invention provides for methods of treating cardiovascular diseases in a mammal. The methods include a step of administering an effective amount of a botulinum toxin directly to a blood vessel of a mammal thereby treating a cardiovascular disease.Type: GrantFiled: February 1, 2006Date of Patent: May 29, 2007Assignee: Allergan, Inc.Inventors: Gregory F. Brooks, Stephen Donovan